Annals of Surgical Oncology

, Volume 12, Issue 12, pp 1073–1083 | Cite as

Improved Survival Associated With Postoperative Wound Infection in Dogs Treated With Limb-Salvage Surgery for Osteosarcoma

  • B. Duncan X. Lascelles
  • William S. Dernell
  • Maria T. Correa
  • Mary Lafferty
  • Chad M. Devitt
  • Charles A. Kuntz
  • Rodney C. Straw
  • Stephen J. Withrow



Limb-salvage surgery and adjuvant chemotherapy are performed as a treatment of appendicular osteosarcoma in dogs. Approximately 50% of dogs that undergo limb-salvage surgery develop postoperative surgical wound infections. Postoperative surgical infections may affect survival in cancer patients. The purposes of this study were to examine the effect of surgical wound infection on survival, local recurrence, and metastasis in relation to other prognostic factors for dogs with spontaneous osteosarcoma treated with limb-salvage surgery.


Forty-seven client-owned dogs with osteosarcoma of the distal radius were treated with limb-salvage surgery and adjuvant chemotherapy—either carboplatin or carboplatin and doxorubicin. Hazard ratios were estimated by using the Cox proportional hazard model, and survival functions were estimated by using the Kaplan-Meier product-limit life-table method.


Of the 47 dogs in this study, 32 (68%) developed a postoperative wound infection. Infection, dog weight, and extent of the primary tumor (percentage of length) significantly affected survival, and infection and percentage of length significantly affected time to metastasis. None of the variables considered in this study affected local recurrence. Dogs that were diagnosed with an infection were less likely to die (hazard ratio, .446), and dogs with greater body weight and greater percentage length involvement were more likely to die (hazard ratios of 3.37 and 3.66, respectively).


In dogs with osteosarcoma treated with limb-salvage surgery, infection has a positive influence on survival, as does a smaller initial length of radius involved and lower body weight.


Osteosarcoma Canine Limb salvage Postoperative infection. 


  1. 1.
    Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343–50CrossRefPubMedGoogle Scholar
  2. 2.
    Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop 1991;270:159–68Google Scholar
  3. 3.
    Berg J, Weinstein MJ, Schelling SH, Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987–1990). J Am Vet Med Assoc.1992;200:2005–8PubMedGoogle Scholar
  4. 4.
    Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555–60PubMedGoogle Scholar
  5. 5.
    Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76–81PubMedGoogle Scholar
  6. 6.
    LaRue SM, Withrow SJ, Powers BE, et al. Limb-sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 1989;195:1734–44PubMedGoogle Scholar
  7. 7.
    Shapiro W, Fossum T, Kitchell B, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507–11PubMedGoogle Scholar
  8. 8.
    Spodnick G, Berg J, Rand W, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992;200:995–9PubMedGoogle Scholar
  9. 9.
    Maulin G, Matus R, Withrow S. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988;2:177–80Google Scholar
  10. 10.
    Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am Small Anim Pract 1996;26:135–43PubMedGoogle Scholar
  11. 11.
    Thrall DE, Withrow SJ, Powers BE, et al. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Radiat Oncol Biol Phys 1990;18:1351–7PubMedGoogle Scholar
  12. 12.
    Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529–64CrossRefPubMedGoogle Scholar
  13. 13.
    Schantz SP, Skolnik EM, O’Neill JV. Improved survival associated with postoperative wound infection in laryngeal cancer: an analysis of its therapeutic implications. Otolaryngol Head Neck Surg 1980;88:412–7PubMedGoogle Scholar
  14. 14.
    Sensenig DM, Rossi NP, Ehrenhaft JL. Pulmonary resection for bronchogenic carcinoma in geriatric patients. Ann Thorac Surg 1966;2:508–13PubMedCrossRefGoogle Scholar
  15. 15.
    Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med 1972;287:1013–7PubMedCrossRefGoogle Scholar
  16. 16.
    Grandis JR, Snyderman CH, Johnson JT, et al. Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer. Cancer 1992;70:2166–70PubMedGoogle Scholar
  17. 17.
    Jackson RM, Rice DH. Wound infections and recurrence in head and neck cancer. Otolaryngol Head Neck Surg 1990;102:331–3PubMedGoogle Scholar
  18. 18.
    Papachristou DN, Fortner JG. Effect of postoperative wound infection on the course of stage II melanoma. Cancer 1979;43:1106–11PubMedGoogle Scholar
  19. 19.
    Higuchi Y. Antitumor effect of Streptococcus pyogenes by inducing hydrogen peroxide production. Jpn J Cancer Res 1996;87:1271–9PubMedGoogle Scholar
  20. 20.
    Withrow SJ, Liptak JM, Straw RC, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol 2004;11:705–13CrossRefPubMedGoogle Scholar
  21. 21.
    Straw RC, Powers BE, Withrow SJ, et al. The effect of intramedullary polymethylmethacrylate on healing of intercalary cortical allografts in a canine model. J Orthop Res 1992;10:434–9CrossRefPubMedGoogle Scholar
  22. 22.
    Dernell W, Withrow SJ, Straw RC, et al. Clinical response to antibiotic impregnated polymethyl methacrylate bead implantation of dogs with severe infections after limb sparing with allograft replacement; 18 cases (1994–1996). Vet Comp Orthop Traumatol 1998;11:94–9Google Scholar
  23. 23.
    Sturgis EM, Congdon DJ, Mather FJ, Miller RH. Perioperative transfusion, postoperative infection, and recurrence of head and neck cancer. South Med J 1997;90:1217–24PubMedGoogle Scholar
  24. 24.
    Kressner U, Graf W, Mahteme H, et al. Septic complications and prognosis after surgery for rectal cancer. Dis Colon Rectum 2002;45:316–21CrossRefPubMedGoogle Scholar
  25. 25.
    Garzotto CK, Berg J, Hoffmann WE, Rand WM. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000;14:587–92CrossRefPubMedGoogle Scholar
  26. 26.
    Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423–31PubMedGoogle Scholar
  27. 27.
    Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 1991;67:126–34PubMedGoogle Scholar
  28. 28.
    Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699–705PubMedGoogle Scholar
  29. 29.
    Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848–58PubMedGoogle Scholar
  30. 30.
    Ehrhart N, Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990–1996). J Am Vet Med Assoc 1998;213:1002–6PubMedGoogle Scholar
  31. 31.
    Dick HM, Strauch RJ. Infection of massive bone allografts. Clin Orthop 1994(306):46–53Google Scholar
  32. 32.
    Mankin HJ, Gebhardt MC, Jennings LC, et al. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop 1996(324):86–97Google Scholar
  33. 33.
    Gebhardt MC, Flugstad DI, Springfield DS, Mankin HJ. The use of bone allografts for limb salvage in high-grade extremity osteosarcoma. Clin Orthop 1991(270):181–96Google Scholar
  34. 34.
    Brown DC, Conzemius MG, Shofer F, Swann H. Epidemiologic evaluation of postoperative wound infections in dogs and cats. J Am Vet Med Assoc 1997;210:1302–6PubMedGoogle Scholar
  35. 35.
    Dernell WS, Withrow SJ, Straw RC, et al. Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer. Anticancer Res 1997;17:4499–505PubMedGoogle Scholar
  36. 36.
    Ehrhart N, Dernell WS, Ehrhart EJ, et al. Effects of a controlled-release cisplatin delivery system used after resection of mammary carcinoma in mice. Am J Vet Res 1999;60:1347–51PubMedGoogle Scholar
  37. 37.
    Mnaymneh W, Malinin TI, Lackman RD, et al. Massive distal femoral osteoarticular allografts after resection of bone tumors. Clin Orthop 1994(303):103–15Google Scholar
  38. 38.
    Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for treatment of metastatic canine osteosarcoma. Eur J Exp Musculoskel Res 1995;4:105–10Google Scholar
  39. 39.
    Misdorp W, Hart AA. Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Cancer Inst 1979;62:537–45PubMedGoogle Scholar
  40. 40.
    Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 1990;72:643–53PubMedGoogle Scholar
  41. 41.
    Bech-Nielsen S, Brodey RS, Fidler IJ, et al. The effect of BCG on in vitro immune reactivity and clinical course in dogs treated surgically for osteosarcoma. Eur J Cancer 1977;13:33–41PubMedGoogle Scholar
  42. 42.
    Eilber FR, Townsend C, Morton DL. Osteosarcoma. Results of treatment employing adjuvant immunotherapy. Clin Orthop 1975(111):94–100PubMedGoogle Scholar
  43. 43.
    Owen LN, Bostock DE. Effects of intravenous BCG in normal dogs and in dogs with spontaneous osteosarcoma. Eur J Cancer 1974;10:775–80PubMedGoogle Scholar
  44. 44.
    Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666–70PubMedGoogle Scholar
  45. 45.
    Oettgen HF, Carswell EA, Kassel RL, et al. Endotoxin-induced tumor necrosis factor. Recent Results Cancer Res 1980;75:207–12PubMedGoogle Scholar
  46. 46.
    Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999;17:37–41PubMedGoogle Scholar
  47. 47.
    Watanabe N, Niitsu Y, Yamauchi N, et al. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients. Immunopharmacol Immunotoxicol 1988;10:53–65PubMedGoogle Scholar
  48. 48.
    Suzuki K, Tsuge I, Ito Y, et al. Histological effect of intranodal injection of the streptococcal preparation OK-432 for cervical lymph node metastases of malignant head and neck tumors. Acta Otolaryngol Suppl 1996;525:125–8PubMedGoogle Scholar
  49. 49.
    Kimura T, Suzuki K, Motai H, et al. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Acta Otolaryngol Suppl 1996;525:135–41PubMedGoogle Scholar
  50. 50.
    Taradi M, Urano M, Taradi SK, Maruyama Y. Augmentation of mouse natural killer cell activity by combined hyperthermia and streptococcal preparation, OK-432 (Picibanil) treatment. Int J Hyperthermia 1991;7:653–65PubMedGoogle Scholar
  51. 51.
    Ozaki S, Suginoshita T, Watanabe T, Obayashi H. Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2− T-cells. Cancer Res 1990;50:4630–4PubMedGoogle Scholar
  52. 52.
    Asano T, McWatters A, An T, et al. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther 1994;268:1032–9PubMedGoogle Scholar
  53. 53.
    Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother 1993;14:286–92PubMedGoogle Scholar
  54. 54.
    Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995;1:1595–601PubMedGoogle Scholar
  55. 55.
    Youdim S. Resistance to tumor growth mediated by Listeria monocytogenes. Destruction of experimental malignant melanoma by LM-activated peritoneal and lymphoid cells. J Immunol 1976;116:579–84PubMedGoogle Scholar
  56. 56.
    Youdim S. Destruction of experimental malignant melanoma by mediators of cellular immunity. Cancer Res 1977;37:572–7PubMedGoogle Scholar
  57. 57.
    Hunter CA, Yu D, Gee M, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol 2001;166:5878–81PubMedGoogle Scholar
  58. 58.
    Thomas-Tikhonenko A, Hunter CA. Infection and cancer: the common vein. Cytokine Growth Factor Rev 2003;14:67–77CrossRefPubMedGoogle Scholar
  59. 59.
    Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996;56:2434–9PubMedGoogle Scholar
  60. 60.
    Mizutani Y, Bonavida B, Koishihara Y, et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995;55:590–6PubMedGoogle Scholar
  61. 61.
    Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1993;72:809–18PubMedGoogle Scholar
  62. 62.
    Walther W, Stein U. Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 1994;120:471–8CrossRefPubMedGoogle Scholar
  63. 63.
    Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 1996;88:1383–92PubMedGoogle Scholar
  64. 64.
    Fujisawa T, Yamaguchi Y. Postoperative immunostimulation after complete resection improves survival of patients with stage I nonsmall cell lung carcinoma. Cancer 1996;78:1892–8CrossRefPubMedGoogle Scholar
  65. 65.
    Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001;90:191–9CrossRefPubMedGoogle Scholar
  66. 66.
    Sandoval BA, Robinson AV, Sulaiman TT, et al. Open versus laparoscopic surgery: a comparison of natural antitumoral cellular immunity in a small animal model. Am Surg 1996;62:625–30; discussion 630–1PubMedGoogle Scholar
  67. 67.
    Kutza J, Gratz I, Afshar M, Murasko DM. The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans. Anesth Analg 1997;85:918–23PubMedGoogle Scholar
  68. 68.
    Page GG, Ben-Eliyahu S, Liebeskind JC. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994;8:241–50CrossRefPubMedGoogle Scholar
  69. 69.
    Knottenbelt CM, Simpson JW, Tasker S, et al. Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. J Small Anim Pract 2000;41:393–7PubMedGoogle Scholar
  70. 70.
    Knapp DW, Chan TC, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801–5PubMedGoogle Scholar
  71. 71.
    Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221–6CrossRefPubMedGoogle Scholar
  72. 72.
    Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214–8CrossRefPubMedGoogle Scholar
  73. 73.
    Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273–8PubMedCrossRefGoogle Scholar
  74. 74.
    Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356–8PubMedGoogle Scholar
  75. 75.
    Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218:1783–6PubMedGoogle Scholar
  76. 76.
    Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T. The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 1997;80:2263–7CrossRefPubMedGoogle Scholar
  77. 77.
    Seay TM, Peretsman SJ, Dixon PS. Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 1996;155:757–62PubMedGoogle Scholar
  78. 78.
    Miclau T, Edin ML, Lester GE, et al. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 1998;16:509–12CrossRefPubMedGoogle Scholar
  79. 79.
    Holtom PD, Pavkovic SA, Bravos PD, et al. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro. J Orthop Res 2000;18:721–7CrossRefPubMedGoogle Scholar
  80. 80.
    Sissi C, Palumbo M. The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anti-Canc Agents 2003;3:439–50CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2005

Authors and Affiliations

  • B. Duncan X. Lascelles
    • 1
  • William S. Dernell
    • 2
  • Maria T. Correa
    • 3
  • Mary Lafferty
    • 2
  • Chad M. Devitt
    • 2
  • Charles A. Kuntz
    • 2
  • Rodney C. Straw
    • 2
  • Stephen J. Withrow
    • 2
  1. 1.Department of Clinical Sciences, College of Veterinary MedicineNorth Carolina State UniversityRaleighNorth Carolina
  2. 2.Animal Cancer Center, Department of Clinical Sciences, College of Veterinary MedicineColorado State UniversityFort Collins
  3. 3.Department of Population Health and Pathobiology, College of Veterinary MedicineNorth Carolina State UniversityRaleigh

Personalised recommendations